Key Findings:  Two modalities, i.e. immunotherapy and cannabis, both that have immunomodulatory effects and may have possible interaction. This study was designed to examine the impact of cannabis-based therapies with that of immunotherapy. The researchers included a total of 140 patients (89 nivolumab alone, 51 nivolumab plus cannabis) with advanced melanoma, non-small cell lung cancer, and renal clear cell carcinoma. Results showed that the use of cannabis during immunotherapy treatment decreased response rate, without affecting progression-free survival or overall survival and without relation to cannabis composition.
Type of Study:  Meta-analysis
Study Sample Size:  140
Study Result:  Inconclusive
Study Location(s):  Israel
Year of Pub:  2019
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source:  Not Applicable